MM
SEC Insider//CIK 0001749623
McKenna Mark C.
CIK 00017496237 companiesNAARDEN, P7
Transactions
50
Companies
7
Filings
11
CIK
0001749623
Recent Transactions
- Award
- Award
- Exercise/Conversion
- Exercise/Conversion
- Award
- Award
- Award
- Award
- Purchase
- Purchase
- Award
- Award
- Award
- Award
- Award
- Disposition to Issuer
- Disposition to Issuer
- Disposition to Issuer
- Disposition to Issuer
- Disposition to Issuer
- Disposition to Issuer
- Disposition to Issuer
- Disposition to Issuer
- Disposition to Issuer
- Exercise/Conversion
- Exercise/Conversion
- Exercise/Conversion
- Exercise/Conversion
- Exercise/Conversion
- Exercise/Conversion
- Sale
- Exercise/Conversion
- Exercise/Conversion
- Sale
- Exercise/Conversion
- Sale
- Exercise/Conversion
- Exercise/Conversion
- Exercise/Conversion
- Sale
- Sale
- Exercise/Conversion
- Exercise/Conversion
- Exercise/Conversion
- Exercise/Conversion
- Sale
- Exercise/Conversion
- Exercise/Conversion
- Sale
- Award
Companies
7- $APGE
Apogee Therapeutics, Inc.
Director
- $BHC
Bausch Health Companies Inc.
President, Salix
- $BBOT
BridgeBio Oncology Therapeutics, Inc.
Former Director
- $NAMS
NewAmsterdam Pharma Co N.V.
Director
- $PCSC
Perceptive Capital Solutions Corp
Director
Prometheus Biosciences, Inc.
Director, President and CEO
- $SYRE
Spyre Therapeutics, Inc.
Director
Recent Filings
11- 4
McKenna Mark C.
Jan 9, 2026
- 4
McKenna Mark C.
Aug 11, 2025
- 4
McKenna Mark C.
Jun 20, 2025
- 4
McKenna Mark C.
Jun 2, 2025
- 4
McKenna Mark C.
Jan 8, 2025
- 4
McKenna Mark C.
Dec 16, 2024
- 4
McKenna Mark C.
Jul 19, 2024
- 4
McKenna Mark C.
Jun 7, 2024
- 4
McKenna Mark C.
Feb 5, 2024
- 4
McKenna Mark C.
Aug 21, 2023
- 4
McKenna Mark C.
Jun 16, 2023
Address
C/O NEWAMSTERDAM PHARMA COMPANY N.V. GOOIMEER 2-35
NAARDEN, P7, 1411 DC